Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's diseaseAdam C. Naj, Charles DeCarli, Eileen H. Bigio et al.|Nature Genetics|2011Cited by 2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteriaBruno Dubois, Cliff R Jack, Harald Hampel et al.|Alzheimer s & Dementia|2016Cited by 1.9k
Alzheimer's diseaseColin L. Masters, Jeffrey L. Cummings, Randall J. Bateman et al.|Nature Reviews Disease Primers|2015Cited by 1.8k
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyChad J. Swanson, Jeffrey L. Cummings, Yong Zhang et al.|Alzheimer s Research & Therapy|2021Cited by 818
On the path to 2025: understanding the Alzheimer’s disease continuumPaul Aisen, Bruno Dubois, Jeffrey L. Cummings et al.|Alzheimer s Research & Therapy|2017Cited by 559